Semaglutide denied as duplicate or overlapping therapy by Anthem?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Anthem typically requires
Anthem's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Anthem angle on Semaglutide
## Why Anthem Denied Semaglutide as "Duplicate Therapy" — and How to Appeal
A duplicate-therapy denial from Anthem means their system flagged semaglutide as overlapping with another medication you are currently prescribed — typically another GLP-1 receptor agonist or a drug Anthem's system codes as having the same mechanism or therapeutic class. This is often a pharmacy-system error rather than a true clinical duplication, and it can be resolved with a targeted appeal.
## Why This Is Frequently an Error
Duplicate-therapy flags are typically generated by automated pharmacy benefit management (PBM) edits, not by clinical review. Common causes include: a prior GLP-1 prescription that is still appearing as active in Anthem's system even though it has been discontinued; two semaglutide products (e.g., different brand names for the same molecule) both appearing on a claim; or a drug in a different class that Anthem's system incorrectly groups with semaglutide. In most cases, documentation showing that the supposed duplicate has been discontinued — or that the two drugs are not therapeutically equivalent — resolves the denial.
## Your Federal Appeal Rights
- ERISA §503 / ACA §2719 internal appeal: Submit within the timeframe on your EOB. Request the specific drug name Anthem identified as the duplicate and the clinical rationale for the flag.
- External review (ACA §2719): Available after the final internal adverse determination, generally within four months of that decision.
- Expedited review: Available if your clinical situation is urgent.
## What to Gather
1. The denial letter identifying the alleged duplicate drug — you need the name of what Anthem says is duplicating semaglutide. 2. Current medication list from your prescriber — with clear notation of what is active, what has been discontinued, and the date of discontinuation. 3. Prescriber letter explaining the clinical distinction: If another drug is still active, your prescriber should explain why both are clinically appropriate and non-redundant for your condition. If the supposed duplicate is discontinued, a simple attestation with the stop date resolves the issue. 4. Pharmacy fill history — showing that the alleged duplicate has not been filled recently, if applicable. 5. FDA-approved prescribing information for both drugs if the appeal turns on therapeutic equivalence — labels define the approved indications and mechanisms.
## Criteria-Mapping Structure
Obtain Anthem's duplicate-therapy policy or the PBM edit criteria. Address each element: (1) name the alleged duplicate, (2) establish its current status (active or discontinued), (3) if active, explain the clinical rationale for concurrent use per chart notes, and (4) cite any guideline organization that supports combination or sequential use if relevant to your condition.
## Key Argument
If the duplicate has been discontinued, the denial is factually incorrect and should be reversed immediately on that basis. If concurrent use is clinically appropriate, the prescriber's explanation of non-redundancy is the key evidence.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →